{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:25Z","timestamp":1792801105102,"version":"4.5.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synaptic dysfunction and degeneration is likely the key pathophysiology for the progression of cognitive decline in various dementia disorders. Synaptic status can be monitored by measuring synaptic proteins in CSF. In this study, both known and new synaptic proteins were investigated and compared as potential biomarkers of synaptic dysfunction, particularly in the context of Alzheimer's disease (AD).<\/jats:p>\n                  <jats:p>Seventeen synaptic proteins were quantified in CSF using two different targeted mass spectrometry assays in the prospective Swedish BioFINDER-2 study. The study included 958 individuals, characterized as having mild cognitive impairment (MCI, n = 205), AD dementia (n = 149) and a spectrum of other neurodegenerative diseases (n = 171), in addition to cognitively unimpaired individuals (CU, n = 443). Synaptic protein levels were compared between diagnostic groups and their associations with cognitive decline and key neuroimaging measures (amyloid-\u03b2-PET, tau-PET and cortical thickness) were assessed.<\/jats:p>\n                  <jats:p>Among the 17 synaptic proteins examined, 14 were specifically elevated in the AD continuum. SNAP-25, 14-3-3 zeta\/delta, \u03b2-synuclein, and neurogranin exhibited the highest discriminatory accuracy in differentiating AD dementia from controls (areas under the curve = 0.81\u20130.93). SNAP-25 and 14-3-3 zeta\/delta also had the strongest associations with tau-PET, amyloid-\u03b2-PET and cortical thickness at baseline and were associated with longitudinal changes in these imaging biomarkers [\u03b2(standard error, SE) = \u22120.056(0.0006) to 0.058(0.005), P &amp;lt; 0.0001]. SNAP-25 was the strongest predictor of progression to AD dementia in non-demented individuals (hazard ratio = 2.11). In contrast, neuronal pentraxins were decreased in all neurodegenerative diseases (except for Parkinson's disease), and NPTX2 showed the strongest associations with subsequent cognitive decline [longitudinal Mini-Mental State Examination: \u03b2(SE) = 0.57(0.1), P \u2264 0.0001; and mPACC: \u03b2(SE) = 0.095(0.024), P \u2264 0.001] across the AD continuum. Interestingly, utilizing a ratio of the proteins that displayed higher levels in AD, such as SNAP-25 or 14-3-3 zeta\/delta, over NPTX2 improved the biomarkers' associations with cognitive decline and brain atrophy.<\/jats:p>\n                  <jats:p>We found 14-3-3 zeta\/delta and SNAP-25 to be especially promising as synaptic biomarkers of pathophysiological changes in AD. Neuronal pentraxins were identified as general indicators of neurodegeneration and associated with cognitive decline across various neurodegenerative dementias. Cognitive decline and brain atrophy were best predicted by ratios of SNAP-25\/NPTX2 and 14-3-3 zeta\/delta\/NPTX2.<\/jats:p>","DOI":"10.1093\/brain\/awae032","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T18:03:38Z","timestamp":1707329018000},"page":"2414-2427","source":"Crossref","is-referenced-by-count":90,"title":["Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases"],"prefix":"10.1093","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-6060","authenticated-orcid":false,"given":"Johanna","family":"Nilsson","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Malm\u00f6, Lund University , 211 46 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Malm\u00f6, Lund University , 211 46 Malm\u00f6 , Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital , 205 02 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner S","family":"Brum","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"},{"name":"Graduate Program in Biological Sciences: Biochemistry, Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre 90035-003 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Malm\u00f6, Lund University , 211 46 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Ashton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"},{"name":"Centre for Age-Related Medicine, Stavanger University Hospital , 4011 Stavanger , Norway"},{"name":"Department of Old Age Psychiatry, Maurice Wohl Clinical Neuroscience Institute, King\u2019s College London , London SE5 9RX , UK"},{"name":"NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust , London SE5 8AF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-8788","authenticated-orcid":false,"given":"Nicola","family":"Spotorno","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Malm\u00f6, Lund University , 211 46 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Malm\u00f6, Lund University , 211 46 Malm\u00f6 , Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital , 205 02 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-6193","authenticated-orcid":false,"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 431 30 M\u00f6lndal , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 431 30 M\u00f6lndal , Sweden"},{"name":"Fluid Biomarker Laboratory, UK Dementia Research Institute at UCL , London WC1E 6BT , UK"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology , London WC1N 3BG , UK"},{"name":"Hong Kong Center for Neurodegenerative Diseases , Hong Kong , China"},{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison , Madison, WI 53792 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 431 30 M\u00f6lndal , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , S-431 80 M\u00f6lndal , Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 431 30 M\u00f6lndal , Sweden"},{"name":"Paris Brain Institute, ICM, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne University , 75646 Paris , France"},{"name":"Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC , Hefei 230036 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Malm\u00f6, Lund University , 211 46 Malm\u00f6 , Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital , 205 02 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024070507234701600_awae032-B1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer\u2019s disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B2","author":"World Health Organization"},{"key":"2024070507234701600_awae032-B3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"2024070507234701600_awae032-B4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"2024070507234701600_awae032-B5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"2024070507234701600_awae032-B6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med."},{"key":"2024070507234701600_awae032-B7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","article-title":"The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease","volume":"82","author":"Spires-Jones","year":"2014","journal-title":"Neuron"},{"key":"2024070507234701600_awae032-B8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","article-title":"Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Article","volume":"20","author":"Davidsson","year":"1999","journal-title":"Electrophoresis"},{"key":"2024070507234701600_awae032-B9","doi-asserted-by":"crossref","first-page":"1177271920950319","DOI":"10.1177\/1177271920950319","article-title":"Fluid biomarkers for synaptic dysfunction and loss","volume":"15","author":"Camporesi","year":"2020","journal-title":"Biomark Insights."},{"key":"2024070507234701600_awae032-B10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/brain\/awaa395","article-title":"Untangling the association of amyloid-\u03b2 and tau with synaptic and axonal loss in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"2024070507234701600_awae032-B11","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/dad2.12179","article-title":"Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease","volume":"13","author":"Nilsson","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"2024070507234701600_awae032-B12","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1093\/brain\/awaa325","article-title":"Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics","volume":"143","author":"Tijms","year":"2020","journal-title":"Brain"},{"key":"2024070507234701600_awae032-B13","author":"Hansson"},{"key":"2024070507234701600_awae032-B14","first-page":"591","article-title":"Diagnostic and statistical manual of mental disorders","volume":"21","author":"Edition","year":"2013","journal-title":"Am Psychiatric Assoc"},{"key":"2024070507234701600_awae032-B15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"2024070507234701600_awae032-B16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","article-title":"Cognitive effects of Lewy body pathology in clinically unimpaired individuals","volume":"29","author":"Palmqvist","year":"2023","journal-title":"Nat Med."},{"key":"2024070507234701600_awae032-B17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"2024070507234701600_awae032-B19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for Parkinson disease","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch Neurol."},{"key":"2024070507234701600_awae032-B20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord."},{"key":"2024070507234701600_awae032-B21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"2024070507234701600_awae032-B22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"2024070507234701600_awae032-B23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B24","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat Med."},{"key":"2024070507234701600_awae032-B25","doi-asserted-by":"crossref","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","article-title":"Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2 (1\u201342), pTau and tTau CSF immunoassays","volume":"9","author":"Blennow","year":"2019","journal-title":"Sci Rep."},{"key":"2024070507234701600_awae032-B26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u2018Mini-mental state\u2019: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res."},{"key":"2024070507234701600_awae032-B27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol."},{"key":"2024070507234701600_awae032-B28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","article-title":"Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: the PACC5","volume":"3","author":"Papp","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"2024070507234701600_awae032-B29","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1038\/s41467-022-34129-4","article-title":"Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease","volume":"13","author":"Pichet Binette","year":"2022","journal-title":"Nat Commun."},{"key":"2024070507234701600_awae032-B30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol Neurodegener."},{"key":"2024070507234701600_awae032-B31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","article-title":"The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease","volume":"8","author":"Ohrfelt","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"2024070507234701600_awae032-B32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024070507234701600_awae032-B33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Ann Neurol."},{"key":"2024070507234701600_awae032-B34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B35","first-page":"152","article-title":"14-3-3 proteins in neurological disorders","volume":"3","author":"Foote","year":"2012","journal-title":"Int J Biochem Mol Biol."},{"issue":"7","key":"2024070507234701600_awae032-B36","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1093\/brain\/awac484","article-title":"Proteomic clusters underlie heterogeneity in preclinical Alzheimer\u2019s disease progression","volume":"146","author":"Wisch","year":"2022","journal-title":"Brain"},{"issue":"1","key":"2024070507234701600_awae032-B37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-023-00638-z","article-title":"Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease","volume":"18","author":"Modeste","year":"2023","journal-title":"Mol Neurodegener"},{"key":"2024070507234701600_awae032-B38","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/alz.12809","article-title":"Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders","volume":"19","author":"Nilsson","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.29287","article-title":"Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson's disease and related disorders","volume":"38","author":"Nilsson","year":"2023","journal-title":"Mov Disord."},{"key":"2024070507234701600_awae032-B40","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40520-019-01326-z","article-title":"A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment","volume":"32","author":"Mavroudis","year":"2020","journal-title":"Aging Clin Exp Res"},{"key":"2024070507234701600_awae032-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-0801-2","article-title":"Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment","volume":"10","author":"Liu","year":"2020","journal-title":"Transl Psychiatry."},{"key":"2024070507234701600_awae032-B42","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","article-title":"Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease","volume":"5","author":"Galasko","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"2024070507234701600_awae032-B43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","article-title":"Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer\u2019s disease and frontotemporal dementia","volume":"15","author":"Das","year":"2023","journal-title":"Alzheimers Res Ther."},{"key":"2024070507234701600_awae032-B44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of \u03b1-synuclein","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J Parkinsons Dis."},{"key":"2024070507234701600_awae032-B45","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"U\u00e9da","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"2024070507234701600_awae032-B46","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","article-title":"Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer\u2019s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies","volume":"15","author":"Oeckl","year":"2016","journal-title":"Mol Cell Proteomics."},{"key":"2024070507234701600_awae032-B47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/jnnp-2020-324306","article-title":"Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer\u2019s disease","volume":"92","author":"Halbgebauer","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2024070507234701600_awae032-B48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","article-title":"Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2020","journal-title":"J Proteome Res."},{"key":"2024070507234701600_awae032-B49","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1002\/alz.13103","article-title":"Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B50","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1111\/ejn.15656","article-title":"Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review","volume":"56","author":"Saunders","year":"2022","journal-title":"Eur J Neurosci"},{"key":"2024070507234701600_awae032-B51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0896-6273(03)00463-X","article-title":"Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity","volume":"39","author":"Xu","year":"2003","journal-title":"Neuron"},{"key":"2024070507234701600_awae032-B52","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1523\/JNEUROSCI.2768-16.2016","article-title":"Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses","volume":"37","author":"Lee","year":"2017","journal-title":"J Neurosci"},{"issue":"7\u20138","key":"2024070507234701600_awae032-B53","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/prca.201400178","article-title":"Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) CSF","volume":"9","author":"Spellman","year":"2015","journal-title":"Proteomics Clin Appl"},{"key":"2024070507234701600_awae032-B54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbi.2016.07.148","article-title":"Neuronal pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer\u2019s disease spectrum","volume":"58","author":"Swanson","year":"2016","journal-title":"Brain Behav Immun."},{"key":"2024070507234701600_awae032-B55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.12688\/f1000research.15095.1","article-title":"Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer\u2019s disease progression","volume":"7","author":"Begcevic","year":"2018","journal-title":"F1000Res"},{"key":"2024070507234701600_awae032-B56","doi-asserted-by":"crossref","first-page":"97.e1","DOI":"10.1016\/j.neurobiolaging.2020.03.013","article-title":"Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer\u2019s disease: A 24-month follow-up study","volume":"93","author":"Lim","year":"2020","journal-title":"Neurobiol Aging."},{"key":"2024070507234701600_awae032-B57","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease","volume":"17","author":"Libiger","year":"2021;","journal-title":"Alzheimers Dement."},{"key":"2024070507234701600_awae032-B58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/cells10010038","article-title":"Pathologically decreased CSF levels of synaptic marker NPTX2 in DLB are correlated with levels of alpha-synuclein and VGF","volume":"10","author":"Boiten","year":"2020","journal-title":"Cells"},{"key":"2024070507234701600_awae032-B59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-220318","article-title":"A combination of neurofilament light, glial fibrillary acidic protein, and neuronal pentraxin-2 discriminates between frontotemporal dementia and other dementias","volume":"90","author":"Bolsewig","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"2024070507234701600_awae032-B60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-021-00499-4","article-title":"A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study","volume":"16","author":"Bergstr\u00f6m","year":"2021","journal-title":"Mol Neurodegener."},{"key":"2024070507234701600_awae032-B61","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1523\/JNEUROSCI.16-08-02463.1996","article-title":"Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity","volume":"16","author":"Tsui","year":"1996","journal-title":"J Neurosci"},{"key":"2024070507234701600_awae032-B62","doi-asserted-by":"crossref","first-page":"e23798","DOI":"10.7554\/eLife.23798","article-title":"NPTX2 and cognitive dysfunction in Alzheimer's disease","volume":"6","author":"Xiao","year":"2017","journal-title":"Elife"},{"key":"2024070507234701600_awae032-B63","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/nn.2621","article-title":"Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons","volume":"13","author":"Chang","year":"2010","journal-title":"Nat Neurosci."},{"key":"2024070507234701600_awae032-B64","doi-asserted-by":"crossref","first-page":"10867","DOI":"10.3390\/ijms231810867","article-title":"Evaluation of synaptic and axonal dysfunction biomarkers in Alzheimer\u2019s disease and mild cognitive impairment based on CSF and bioinformatic analysis","volume":"23","author":"Dulewicz","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awae032\/58180960\/awae032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/147\/7\/2414\/58447256\/awae032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/147\/7\/2414\/58447256\/awae032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T03:27:35Z","timestamp":1720150055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/147\/7\/2414\/7603216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":64,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awae032","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,2,7]]}}}